From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Summary Current therapies for Alzheimer’s disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy. An alternative approach is to directly activate cholinergic receptors responsible for learning and memory. The M1-muscarinic acetylcholine (M1) receptor is the target of choice but has been hampered by adverse effects. Here we aimed to design the drug properties needed for a well-tolerated M1-agonist with the potential to alleviate cognitive loss by taking a stepwise translational approach from atomic structure, cell/tissue-based assays, evaluation in preclinical species, clinical safety testing, and finally establishing activity in memory centers in humans. Through this approach, we rationally designed the optimal properties, including selectivity and partial agonism, into HTL9936—a potential candidate for the treatment of memory loss in Alzheimer’s disease. More broadly, this demonstrates a strategy for targeting difficult GPCR targets from structure to clinic. Graphical abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
A new method for off-line removal of ocular artifact
Gratton, G., Coles, M. G. H., & Donchin, E. (1983) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(83)90135-9 · Cited by 5,055
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Self-citation(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
The functional significance of delta oscillations in cognitive processing
Harmony, T. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00083 · Cited by 788
Myhrer, T. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00268-0 · Cited by 472
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders
Conn, P. J., Jones, C. K., & Lindsley, C. W. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.002 · Cited by 286
Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs
Congreve, M., Oswald, C., & Marshall, F. H. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.05.010 · Cited by 123
Self-citation
Cited by
Cheng, F., Wang, F., Tang, J., Zhou, Y., Fu, Z., Zhang, P., Haines, J. L., Leverenz, J. B., Gan, L., Hu, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101379 · Cited by 63
Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022) · Neuronal Signaling · doi:10.1042/ns20210004 · Cited by 60
Self-citationVuckovic, Z., Wang, J., Pham, V., Mobbs, J. I., Belousoff, M. J., Bhattarai, A., Burger, W. A., Thompson, G., Yeasmin, M., Nawaratne, V., et al. (2023) · eLife · doi:10.7554/elife.83477 · Cited by 34
Self-citationYang, X., Ding, Z., Peng, L., Song, Q., Zhang, D., Cui, F., Xia, C., Li, K., Yin, H., Li, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34364-9 · Cited by 6
Metadata
- Authors
- Brown, A. J. H., Bradley, S. J., Marshall, F. H., Brown, G. A., Bennett, K. A., Brown, J., Cansfield, J. E., Cross, D. M., de Graaf, C., Hudson, B. D., Dwomoh, L., Dias, J. M., Errey, J. C., Hurrell, E., Liptrot, J., Mattedi, G., Molloy, C., Nathan, P. J., Okrasa, K., Osborne, G., Patel, J. C., Pickworth, M., Robertson, N., Shahabi, S., Bundgaard, C., Phillips, K., Broad, L. M., Goonawardena, A. V., Morairty, S. R., Browning, M., Perini, F., Dawson, G. R., Deakin, J. F. W., Smith, R. T., Sexton, P. M., Warneck, J., Vinson, M., Tasker, T., Tehan, B. G., Teobald, B., Christopoulos, A., Langmead, C. J., Jazayeri, A., Cooke, R. M., Rucktooa, P., Congreve, M. S., Weir, M., & Tobin, A. B.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 184
- Issue
- 24
- Pages
- 5886-5901.e22
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W3217131733
- Cited by
- 96
- References
- 11
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease. https://app.cochat.ai/papers/10.1016/j.cell.2021.11.001
- The paper
- Brown, A. J. H., Bradley, S. J., Marshall, F. H., Brown, G. A., Bennett, K. A., Brown, J., Cansfield, J. E., Cross, D. M., de Graaf, C., Hudson, B. D., Dwomoh, L., Dias, J. M., Errey, J. C., Hurrell, E., Liptrot, J., Mattedi, G., Molloy, C., Nathan, P. J., Okrasa, K., . . . Tobin, A. B. (2021). From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease. Cell. https://doi.org/10.1016/j.cell.2021.11.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.